500 participants
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-26
- Start Date:
- 2025-09-04
- Completion:
- 2028-04-17
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- DRUG
No Results Yet